Stay updated on Pembrolizumab & Lanreotide for GI NETs Clinical Trial
Sign up to get notified when there's something new on the Pembrolizumab & Lanreotide for GI NETs Clinical Trial page.

Latest updates to the Pembrolizumab & Lanreotide for GI NETs Clinical Trial page
- Check5 days agoNo Change Detected
- Check12 days agoNo Change Detected
- Check19 days agoChange DetectedSite revision history shows an addition of v3.5.0 and deletion of v3.4.3.SummaryDifference0.1%

- Check26 days agoChange DetectedRevision updated from v3.4.2 to v3.4.3 on the page.SummaryDifference0.1%

- Check55 days agoChange DetectedRevision: v3.4.2 is added, replacing earlier revisions. The funding-lapse notice and Revision v3.4.1 have been removed.SummaryDifference0.4%

- Check62 days agoChange DetectedAdded a site-wide notice about possible delays due to funding, and updated the page revision to v3.4.1. The previous revision was v3.4.0.SummaryDifference0.4%

- Check69 days agoChange DetectedUI updates include a new 'Show glossary' option and minor text changes such as capitalization of labels and an updated revision/version to v3.4.0. No substantive study content, outcomes, or eligibility details were altered.SummaryDifference0.2%

- Check83 days agoChange DetectedThe page shows an administrative revision label: v3.3.4, replacing the previous v3.3.3. No core study content, eligibility criteria, locations, or outcomes were changed.SummaryDifference0.1%

Stay in the know with updates to Pembrolizumab & Lanreotide for GI NETs Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Pembrolizumab & Lanreotide for GI NETs Clinical Trial page.